Anbio Biotechnology (NNNN) Other Accumulated Expenses (2023 - 2025)

Anbio Biotechnology (NNNN) has 3 years of Other Accumulated Expenses data on file, last reported at $87836.0 in Q4 2025.

• On a quarterly basis, Other Accumulated Expenses fell 16.33% year-over-year to $87836.0 in Q4 2025; TTM through Dec 2025 was $87836.0, a 16.33% decrease from a year earlier, with the FY2025 full-year figure at $87836.0, down 16.33% from the prior year.
• Other Accumulated Expenses for Q4 2025 stood at $87836.0, down from $70.8 billion in the prior quarter.
• Over the last five years, Other Accumulated Expenses for NNNN reached as high as $70.8 billion in Q2 2025 and fell as low as $87836.0 in Q4 2025.
• Historically, Other Accumulated Expenses has averaged $17.7 billion across 3 years, with a median of $135444.0 in 2023.
• Across the five-year window, Other Accumulated Expenses tumbled 36.72% in 2024 and declined 16.33% in 2025, its largest moves.
• Year by year, Other Accumulated Expenses stood at $165909.0 in 2023, then tumbled by 36.72% to $104979.0 in 2024, then decreased by 16.33% to $87836.0 in 2025.
• Per Business Quant data, the three most recent Other Accumulated Expenses figures were $87836.0 in Q4 2025, $70.8 billion in Q2 2025, and $104979.0 in Q4 2024.